HYFT (MindWalk Holdings) Research & Development: $3.64 Mil (TTM As of Jan. 2026)


HYFT MindWalk Holdings Corp HYFT
38 GF Score
Price $1.52
GF Value $0.61
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is MindWalk Holdings Research & Development?

MindWalk Holdings HYFT -2.25% 38 Research & Development is $3.64 Mil as of Jan. 2026. GuruFocus rates HYFT with a GF Score™ of 38/100 and a GF Value™ of $0.61 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MindWalk Holdings's Research & Development for the three months ended in Jan. 2026 was $0.88 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 was $3.64 Mil.

MindWalk Holdings  (NAS:HYFT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MindWalk Holdings Research & Development Related Terms

MindWalk Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for MindWalk Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindWalk Holdings Research & Development Chart

MindWalk Holdings Annual Data
Trend Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 6.07 10.46 2.96 3.54

MindWalk Holdings Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 1.11 0.77 0.88 0.88
HYFT
38GF Score
MindWalk Holdings Corp HYFT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindWalk Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.64 Mil mean?
MindWalk Holdings (HYFT) has a Research & Development of $3.64 Mil as of Jan. 2026. Research and development expense is the total cost for research and development activities. View historical data on MindWalk Holdings and its competitors.
Is MindWalk Holdings' Research & Development too high?
MindWalk Holdings' current Research & Development is $3.64 Mil. Overall, MindWalk Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' Research & Development compare to GANX and EXOZ?
MindWalk Holdings' Research & Development of $3.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MindWalk Holdings and its competitors. MindWalk Holdings's current Research & Development is $3.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.52 — trading 148.4% above its estimated fair value. The current Research & Development is $3.64 Mil. MindWalk Holdings' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current Research & Development is $3.64 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MindWalk Holdings (HYFT) Overvalued in 2026?

Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued. The current stock price of $1.52 is trading 148.4% above its estimated GF Value™ of $0.61. GuruFocus considers MindWalk Holdings to be Significantly Overvalued.

Key valuation signals for HYFT:

  • Research & Development: $3.64 Mil
  • GF Value™: $0.61 vs. price of $1.52 (148.4% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MindWalk Holdings Business Description

Other Exchanges TQB0:Germany
Address Industrious 823 Congress Avenue, Suite 300, Austin, TX, USA, 78701
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
38GF Score

Get the complete analysis for HYFT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price
$0.61
GF Value